Alert Icon

Beware of scams

We are aware of scams coming from email and social media where people try to impersonate us. We will never ask you for money or your bank details.

Learn more about what to look out for and how to protect yourself

British Patient Capital comments on the one-year anniversary of the launch of The Kalifa Review

Insights 23 February 2022

Judith Hartley, CEO of British Patient Capital, comments on the one-year anniversary of the launch of The Kalifa Review of UK FinTech:

The launch of the Kalifa Review in February last year was an important milestone in the development of the UK’s fintech sector, acknowledging both the important role the sector is playing in the economy and ensuring the UK can retain its position as the fintech capital of Europe. Over the past year, we have seen considerable market activity with phenomenal levels of investment. In our own underlying portfolio, we saw banking software developer Thought Machine and insurtech business Zego become unicorns in 2021, and digital bank Revolut became a decacorn when it was valued at $3 billion in a funding round in July. By any measure, it has been an exceptional time for UK fintech. But structural issues remain. While funding nearly doubled in 2021, the majority of private market capital continues to come from outside the country, with UK institutional investors in particular being reticent when it comes to investing in domestic innovation. By not investing in UK venture and venture growth funds, UK institutional investors are failing to capture the value being created by fast-growing businesses operating in some of the most exciting and dynamic sectors in the economy. The UK has a history of innovation in the finance sector, and many of our current generation of home-grown start-ups and scale-ups are poised to become global leaders in financial services. Yet, in order to do so, access to capital is crucial. As the largest domestic LP investor in UK venture and venture growth funds, we have deployed over £1.3 billion since our inception in 2018, and while we are sector agnostic, a significant portion of our underlying portfolio companies are in the fintech space. By taking a long-term patient capital approach, institutional investors can fuel the growth of the UK’s most promising and innovative fintech companies, capture the value they create, and help ambitious entrepreneurs on their growth journey.

Further Information

Notes to editors

About British Patient Capital

British Patient Capital is the trading name of British Patient Capital Limited, a wholly-owned commercial subsidiary of British Business Bank plc, the UK government’s economic development bank. It forms part of the British Business Bank’s plc’s commercial arm.

Its mission is to enable long-term investment in innovative firms led by ambitious entrepreneurs who want to build large scale businesses. Launched in June 2018, British Patient Capital has £2.5 billion to invest over 10 years in venture and venture growth capital to support high growth potential innovative UK businesses in accessing the long-term financing they require to scale up. Find out more at British Patient Capital.

British Business Bank plc and its subsidiary entities are not banking institutions and do not operate as such. They are not authorised or regulated by the Prudential Regulation Authority (PRA) or the Financial Conduct Authority (FCA). A complete legal structure chart for British Business Bank plc and its subsidiaries can be found on the British Business Bank plc website.

British Patient Capital makes commitments and invests on its own behalf and on behalf of third-party investors whose investments British Patient Capital manages.